Kazunori Aoki
Chief
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (2)
Tyrosine kinase inhibitors are initially efficacious against anaplastic lymphoma kinase ( ALK ) fusion gene–positive lung adenocarcinoma, but acquired resistance inevitably occurs. Therefore, alternative treatment strategies are needed for tyrosine kinase inhibitor–resistant cases. Although the use of immune checkpoint inhibitors (ICI) has improved the prognosis of patients with lung cancer, patients with AL K + lung adenocarcinoma exhibit little or no response to immunotherapy and the underlying resistance mechanisms remain unknown. In this study, we explored the immunologic status of the tumor microenvironment (TME) in ALK + lung adenocarcinoma tissues. Tumor-infiltrating leukocyte analysis revealed reduced numbers of effector T cells and increased myeloid-derived suppressor cells (MDSC) relative to ALK − lung adenocarcinoma cases, indicating that ALK + lung adenocarcinoma has a myeloid cell–dominant immunosuppressive TME. Single-cell RNA sequencing analysis identified a subset of macrophages that expressed most T cell–attractant chemokines ( CXCL9 , CXCL10 , and CXCL11 ), and the macrophages were inactivated in ALK + lung adenocarcinoma. In contrast, ALK + lung adenocarcinoma expressed high levels of MDSC-attractant chemokines ( CXCL1 and CXCL8 ). In addition, ALK + lung adenocarcinoma showed higher levels of IL6, an MDSC-inducing cytokine, than ALK – lung adenocarcinoma. An IL6R inhibitor transformed the TME in a murine ALK + lung adenocarcinoma model, shifting it from an immunosuppressive to a T cell–dominant status. Although ICI monotherapy lacked antitumor effects, a combination of ICI and the IL6R inhibitor had significant antitumor effects in mice. Our findings illustrate the molecular basis of fusion gene–mediated immunosuppressive TMEs, providing a rationale for a novel combination immunotherapy for ALK + lung adenocarcinoma. See related Spotlight by Vitale and Bria, p.1326
Year:
2025
Overcoming resistance to immune checkpoint inhibitors is an important issue in patients with non‐small‐cell lung cancer (NSCLC). Transcriptome analysis shows that adenocarcinoma can be divided into three molecular subtypes: terminal respiratory unit (TRU), proximal proliferative (PP), and proximal inflammatory (PI), and squamous cell carcinoma (LUSQ) into four. However, the immunological characteristics of these subtypes are not fully understood. In this study, we investigated the immune landscape of NSCLC tissues in molecular subtypes using a multi‐omics dataset, including tumor‐infiltrating leukocytes (TILs) analyzed using flow cytometry, RNA sequences, whole exome sequences, metabolomic analysis, and clinicopathologic findings. In the PI subtype, the number of TILs increased and the immune response in the tumor microenvironment (TME) was activated, as indicated by high levels of tertiary lymphoid structures, and high cytotoxic marker levels. Patient prognosis was worse in the PP subtype than in other adenocarcinoma subtypes. Glucose transporter 1 (GLUT1) expression levels were upregulated and lactate accumulated in the TME of the PP subtype. This could lead to the formation of an immunosuppressive TME, including the inactivation of antigen‐presenting cells. The TRU subtype had low biological malignancy and “cold” tumor‐immune phenotypes. Squamous cell carcinoma (LUSQ) did not show distinct immunological characteristics in its respective subtypes. Elucidation of the immune characteristics of molecular subtypes could lead to the development of personalized immune therapy for lung cancer. Immune checkpoint inhibitors could be an effective treatment for the PI subtype. Glycolysis is a potential target for converting an immunosuppressive TME into an antitumorigenic TME in the PP subtype.
Year:
2024
Collaborators (5)
Akiyoshi Hirayama
Keio University
Yasuhito Arai
Senior researcher
National Cancer Center Research Institute
Yae Kanai
Keio University School of Medicine
Kouichi Ozaki
Visittng Professor
National Center for Geriatrics and Gerontology
Tomoyoshi Soga
Keio University
Make your next move.
Prepare your application
Review drafts before you send them.